The unnamed 60-year-old sought help from medics in Paris, France after suddenly developing health just four weeks after being jabbed with a Covid vaccine.

The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, and carrying out value-driven share buybacks.

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

The impact of AI in the workplace is already profound, but that impact is expected to grow exponentially in the coming years, ...

Pfizer’s Q1 earnings call delivered a rollercoaster of cautious optimism. CEO Albert Bourla credited solid execution in ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

As if Wall Street wasn't troubled enough, the market has been in turmoil across early June thanks to the resurgence of geopolitical unrest in the Middle East. Throw in continued uncertainty ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Millions of women in the United States trust the safety of their birth control, never imagining it could lead to severe ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

It is hard to think of a less coherent pair of policies: President Trump’s tax policy encourages the very offshoring that his ...